triple glp 1 gip glucagon receptor agonist GLP-1/GIP/Glucagon Courtesy ref no. 43-Schematic demonstrating

Exenatide targets the GLP-1 receptors located at the choroid plexus epithelium, the structure responsible for the majority of CSF secretion in the brain [16, 17]

Journal reference: Rodriguez, M

Administration of exendin-4 into the shell of the NAcc decreases sucrose reward behavior in the progressive ratio (PR) operant conditioning test [701]

However, this evidence is limited, inconsistent, and does not demonstrate clinically significant effects comparable to prescription GLP-1 agonists

Clinical Efficacy: Evidence from Major Trials Weight Loss Outcomes in Non-Diabetic Patients The clinical efficacy of GLP-1 agonists for weight loss in non-diabetic patients has been demonstrated across multiple large-scale randomized controlled trials

The regain is associated with an increase in risk factors for cardiometabolic conditions like diabetes and heart disease